We offer collaborative support and a broad portfolio of reagents that are used in research labs studying coronaviruses and other emerging viral diseases. We support scientists working to develop vaccines and to answer questions about viral pathology and treatment including:
- How does the virus enter human cells?
- How does the virus make people sick?
- What treatments can be used to alleviate symptoms?
- How can immunity to the virus be gained?
Host Immune Response
The innate immune response includes activation of inflammasomes and cytokine release. Caspase-1 activity, the release of cytokines (e.g., IL-1-β) or damage-associated molecular patterns (DAMPs) can all be used to evaluate aspects of the innate immune response in infected cells.
The adaptive immune response includes production of neutralizing antibodies and antibodies with ADCC activity, in addition to T cell activation. Promega’s portfolio of bioluminescent reporter assays supports the development of vaccines to induce antibody response. Cytokine detection assays can be used to monitor T cell activation.
RNA Production for Vaccine Research and Development
Transcribed RNA is required for vaccine production, viral standards, and basic viral research. For in vivo and in vitro studies, RiboMAX® RNA Production System generates a large quantity of high-quality RNA or mRNA from a DNA template without the need for mammalian cells or cell components. These in-vitro transcribed viral RNA or mRNA transcripts, typically encoding a disease-specific antigen such as the spike protein of a coronavirus, may be used as inoculation material for viral infection studies. If the transcribed mRNA is to be used as a therapeutic, the mRNA encoding a desirable protein can be packaged as necessary for delivery to the tissue of interest.
RNA Production Products and Resources
RNA Production Product
RiboMAX™ in vitro transcription system produces 2–5mg/ml RNA in a 1ml reaction.